Cargando…
The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy
Purpose: To investigate the prognostic significance of diabetes mellitus (DM) in patients with high risk acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (pPCI) in the era of potent antithrombotics. Methods: Data from 1230 ST-segment elevation myocardial infa...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464834/ https://www.ncbi.nlm.nih.gov/pubmed/32781780 http://dx.doi.org/10.3390/jcm9082555 |
_version_ | 1783577454706688000 |
---|---|
author | Simek, Stanislav Motovska, Zuzana Hlinomaz, Ota Kala, Petr Hromadka, Milan Knot, Jiri Varvarovsky, Ivo Dusek, Jaroslav Rokyta, Richard Tousek, Frantisek Svoboda, Michal Vodzinska, Alexandra Mrozek, Jan Jarkovsky, Jiri |
author_facet | Simek, Stanislav Motovska, Zuzana Hlinomaz, Ota Kala, Petr Hromadka, Milan Knot, Jiri Varvarovsky, Ivo Dusek, Jaroslav Rokyta, Richard Tousek, Frantisek Svoboda, Michal Vodzinska, Alexandra Mrozek, Jan Jarkovsky, Jiri |
author_sort | Simek, Stanislav |
collection | PubMed |
description | Purpose: To investigate the prognostic significance of diabetes mellitus (DM) in patients with high risk acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (pPCI) in the era of potent antithrombotics. Methods: Data from 1230 ST-segment elevation myocardial infarction (STEMI) patients enrolled in the PRAGUE-18 (prasugrel vs. ticagrelor in pPCI) study were analyzed. Ischemic and bleeding event rates were calculated for patients with and without diabetes. The independent impact of diabetes on outcomes was evaluated after adjustment for outcome predictors. Results: The prevalence of DM was 20% (N = 250). Diabetics were older and more often female. They were more likely to have hypertension, hyperlipoproteinemia, multivessel coronary disease and left main disease, and be obese. The primary net-clinical endpoint (EP) containing death, spontaneous nonfatal MI, stroke, severe bleeding, and revascularization at day 7 occurred in 6.1% of patients with, and in 3.5% of patients without DM (HR 1.8; 95% CI 0.978–3.315; p = 0.055). At one year, the key secondary endpoint defined as cardiovascular death, spontaneous MI, or stroke occurred in 8.8% with, and 5.5% without DM (HR 1.621; 95% CI 0.987–2.661; p = 0.054). In those with DM the risk of total one-year mortality (6.8% vs. 3.9% (HR 1.773; 95% CI 1.001–3.141; p = 0.047)) and the risk of nonfatal reinfarction (4.8% vs. 2.2% (HR 2.177; 95% CI 1.077–4.398; p = 0.026)) were significantly higher compared to in those without DM. There was no risk of major bleeding associated with DM (HR 0.861; 95% CI 0.554–1.339; p = 0.506). In the multivariate analysis, diabetes was independently associated with the one-year risk of reinfarction (HR 2.176; 95% Confidence Interval, 1.055–4.489; p = 0.035). Conclusion: Despite best practices STEMI treatment, diabetes is still associated with significantly worse prognoses, which highlights the importance of further improvements in the management of this high-risk population. |
format | Online Article Text |
id | pubmed-7464834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74648342020-09-04 The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy Simek, Stanislav Motovska, Zuzana Hlinomaz, Ota Kala, Petr Hromadka, Milan Knot, Jiri Varvarovsky, Ivo Dusek, Jaroslav Rokyta, Richard Tousek, Frantisek Svoboda, Michal Vodzinska, Alexandra Mrozek, Jan Jarkovsky, Jiri J Clin Med Article Purpose: To investigate the prognostic significance of diabetes mellitus (DM) in patients with high risk acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (pPCI) in the era of potent antithrombotics. Methods: Data from 1230 ST-segment elevation myocardial infarction (STEMI) patients enrolled in the PRAGUE-18 (prasugrel vs. ticagrelor in pPCI) study were analyzed. Ischemic and bleeding event rates were calculated for patients with and without diabetes. The independent impact of diabetes on outcomes was evaluated after adjustment for outcome predictors. Results: The prevalence of DM was 20% (N = 250). Diabetics were older and more often female. They were more likely to have hypertension, hyperlipoproteinemia, multivessel coronary disease and left main disease, and be obese. The primary net-clinical endpoint (EP) containing death, spontaneous nonfatal MI, stroke, severe bleeding, and revascularization at day 7 occurred in 6.1% of patients with, and in 3.5% of patients without DM (HR 1.8; 95% CI 0.978–3.315; p = 0.055). At one year, the key secondary endpoint defined as cardiovascular death, spontaneous MI, or stroke occurred in 8.8% with, and 5.5% without DM (HR 1.621; 95% CI 0.987–2.661; p = 0.054). In those with DM the risk of total one-year mortality (6.8% vs. 3.9% (HR 1.773; 95% CI 1.001–3.141; p = 0.047)) and the risk of nonfatal reinfarction (4.8% vs. 2.2% (HR 2.177; 95% CI 1.077–4.398; p = 0.026)) were significantly higher compared to in those without DM. There was no risk of major bleeding associated with DM (HR 0.861; 95% CI 0.554–1.339; p = 0.506). In the multivariate analysis, diabetes was independently associated with the one-year risk of reinfarction (HR 2.176; 95% Confidence Interval, 1.055–4.489; p = 0.035). Conclusion: Despite best practices STEMI treatment, diabetes is still associated with significantly worse prognoses, which highlights the importance of further improvements in the management of this high-risk population. MDPI 2020-08-06 /pmc/articles/PMC7464834/ /pubmed/32781780 http://dx.doi.org/10.3390/jcm9082555 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Simek, Stanislav Motovska, Zuzana Hlinomaz, Ota Kala, Petr Hromadka, Milan Knot, Jiri Varvarovsky, Ivo Dusek, Jaroslav Rokyta, Richard Tousek, Frantisek Svoboda, Michal Vodzinska, Alexandra Mrozek, Jan Jarkovsky, Jiri The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy |
title | The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy |
title_full | The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy |
title_fullStr | The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy |
title_full_unstemmed | The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy |
title_short | The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy |
title_sort | effect of diabetes on prognosis following myocardial infarction treated with primary angioplasty and potent antiplatelet therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464834/ https://www.ncbi.nlm.nih.gov/pubmed/32781780 http://dx.doi.org/10.3390/jcm9082555 |
work_keys_str_mv | AT simekstanislav theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT motovskazuzana theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT hlinomazota theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT kalapetr theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT hromadkamilan theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT knotjiri theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT varvarovskyivo theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT dusekjaroslav theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT rokytarichard theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT tousekfrantisek theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT svobodamichal theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT vodzinskaalexandra theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT mrozekjan theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT jarkovskyjiri theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT simekstanislav effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT motovskazuzana effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT hlinomazota effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT kalapetr effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT hromadkamilan effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT knotjiri effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT varvarovskyivo effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT dusekjaroslav effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT rokytarichard effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT tousekfrantisek effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT svobodamichal effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT vodzinskaalexandra effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT mrozekjan effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT jarkovskyjiri effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy AT effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy |